- Home
- ATEX vs CRMD Comparison
ATEX vs CRMD Comparison
Compare ATEX & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- CRMD
- Stock Information
- Founded
- ATEX 1997
- CRMD 2006
- Country
- ATEX United States
- CRMD United States
- Employees
- ATEX N/A
- CRMD N/A
- Industry
- ATEX Telecommunications Equipment
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- CRMD Health Care
- Exchange
- ATEX Nasdaq
- CRMD Nasdaq
- Market Cap
- ATEX 528.1M
- CRMD 464.7M
- IPO Year
- ATEX N/A
- CRMD 2010
- Fundamental
- Price
- ATEX $25.82
- CRMD $12.70
- Analyst Decision
- ATEX Buy
- CRMD Strong Buy
- Analyst Count
- ATEX 2
- CRMD 6
- Target Price
- ATEX $64.00
- CRMD $15.00
- AVG Volume (30 Days)
- ATEX 109.9K
- CRMD 2.1M
- Earning Date
- ATEX 06-25-2025
- CRMD 05-06-2025
- Dividend Yield
- ATEX N/A
- CRMD N/A
- EPS Growth
- ATEX N/A
- CRMD N/A
- EPS
- ATEX N/A
- CRMD 0.28
- Revenue
- ATEX $5,902,000.00
- CRMD $82,553,827.00
- Revenue This Year
- ATEX $49.39
- CRMD $239.16
- Revenue Next Year
- ATEX $2.84
- CRMD $53.17
- P/E Ratio
- ATEX N/A
- CRMD $45.64
- Revenue Growth
- ATEX 66.77
- CRMD N/A
- 52 Week Low
- ATEX $25.35
- CRMD $3.61
- 52 Week High
- ATEX $42.91
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- ATEX 26.79
- CRMD 68.22
- Support Level
- ATEX $27.02
- CRMD $11.88
- Resistance Level
- ATEX $29.14
- CRMD $12.99
- Average True Range (ATR)
- ATEX 1.11
- CRMD 0.49
- MACD
- ATEX -0.03
- CRMD -0.09
- Stochastic Oscillator
- ATEX 11.11
- CRMD 81.87
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.